| Literature DB >> 29773502 |
Ning Li1, Li-Jun Wang2, Bo Jiang2, Shu-Ju Guo2, Xiang-Qian Li2, Xue-Chun Chen3, Jiao Luo1, Chao Li1, Yi Wang4, Da-Yong Shi5.
Abstract
A series of novel pyrimidinedione derivatives were designed and evaluated for in vitro dipeptidyl peptidase-4 (DPP-4) inhibitory activity and in vivo anti-hyperglycemic efficacy. Among them, the representative compounds 11, 15 and 16 showed excellent inhibitory activity of DPP-4 with IC50 values of 64.47 nM, 188.7 nM and 65.36 nM, respectively. Further studies revealed that compound 11 was potent in vivo hypoglycemic effect. The structure-activity relationships of these pyrimidinedione derivatives had been discussed, which would be useful for developing novel DPP-4 inhibitors as treating type 2 diabetes.Entities:
Keywords: DPP-4 inhibitor; Molecular hybrid; Pyrimidinedionederivatives; SARs; Type 2 diabetes
Mesh:
Substances:
Year: 2018 PMID: 29773502 DOI: 10.1016/j.bmcl.2018.05.022
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823